Described are compositions comprising nucleic acids encoding CD3-half-BiTE, CXCL9, CTLA-4 scFv, and IL-12for use in treating cancer. Methods of analyzing CXCR3 expression in a tumor to identify subjects likely to respond to the compositions are also described.

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

The systems and methods disclosed herein relate generally to microbubble-assisted delivery of a therapeutic agent, such as a chemotherapeutic agent, to cells or tissue of interest, either in vitro or in vivo, that can be activated by directed ultrasound irradiation. For example, hydrophobic sonosensitizers can be incorporated in microbubble complexes to provide improved sonodynamic therapies.

Disclosed herein are embodiments of a functionalized microbubble designed for treating and/or preventing vascular obstructions, including microvascular obstructions. The functionalized microbubble embodiments comprise a microbubble that can be activated upon exposure to ultrasound and further that has a lipid-based shell that is attached to an exteriorly-attached therapeutically active agent, such as a thrombolytic agent. Also disclosed herein are embodiments of a method for making and using the functionalized microbubble embodiments.

The present invention concerns a method for the production of cell-membrane derived nanoparticles, comprising the steps of extracting the cell membranes from cells of two or more different cell lines and fusing them by means of high-pressure homogenisation in the presence of a disperse therapeutic or diagnostic ingredient.

Another object of the present invention are cell-membrane derived nanoparticles enclosing a therapeutic or diagnostic ingredient; these nanoparticles are obtainable by the method of the invention and can be employed as drug delivery systems for medical or diagnostic use.

The present disclosure relates to a method of imaging, involving administration of a bi-phasic formulation followed by application of high frequency sound waves to identify a region of interest. Following identification, a phase shift of the bi-phasic formulation may be activated by a second administration of high frequency sound waves such that gaseous components of the bi-phasic formulation are enlarged and localised at the region of interest.

Delivery of compositions for treatment of skin tissue with photoactive plasmonic nanoparticles and light, with embodiments relating to delivery devices. Treatments are useful for cosmetic, diagnostic and therapeutic applications.

Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.

A drug transdermal delivery system comprises sponge spicules and a low-frequency sonophoresis device, the drug transdermal delivery system firstly applies a low-frequency sonophoresis to skin using the low-frequency sonophoresis device, a surface of the skin is then massaged with the sponge spicules.

Described herein are processes and compositions for ultrasound-triggered liposome payload release, including a process for gelation and a process for enzyme catalysis.